PYC Therapeutics Limited is a biotechnology company based in Australia that focuses on the discovery and development of drug solutions in ribonucleic acid therapeutics. The company's preclinical development programs concentrate on the treatment of retinal and central nervous system diseases, such as retinitis pigmentosa type 11 and autosomal dominant optic atrophy. Since changing its name from Phylogica Limited in November 2019, PYC Therapeutics has continued to work on its drug programs, aimed at improving patient outcomes in these challenging areas.